Sam Altman's reported backing of Merge Labs marks the true beginning of the non-invasive BCI race ag...
The AMW Read
The article introduces a significant non-invasive player in the BCI space backed by a major frontier-lab figure, shifting the competition from medical necessity to general human-AI integration.
NoveltySignificance
Robotics · Player Map
Sam Altman's reported backing of Merge Labs marks the true beginning of the non-invasive BCI race against Neuralink. Merge Labs is aiming for an $850 million valuation by pioneering an interface that uses non-surgical methods like ultrasound and magnetic fields, a stark contrast to implanted devices. This approach to BCI—combining genetic neuron modification and external energy waves—prioritizes widespread human-AI integration over medical necessity. The focus shifts from treating paralysis to enabling general thought-controlled AI, potentially accelerating the timeline for cognitive augmentation.
